Foresite Capital Management V LLC Sells 258,900 Shares of Maze Therapeutics, Inc. $MAZE

Foresite Capital Management V LLC lowered its position in shares of Maze Therapeutics, Inc. (NASDAQ:MAZE) by 75.0% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 86,291 shares of the company’s stock after selling 258,900 shares during the quarter. Maze Therapeutics comprises 2.1% of Foresite Capital Management V LLC’s holdings, making the stock its 6th biggest position. Foresite Capital Management V LLC owned 0.18% of Maze Therapeutics worth $2,238,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of MAZE. Ameritas Investment Partners Inc. increased its position in Maze Therapeutics by 82.6% during the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock worth $42,000 after acquiring an additional 738 shares during the period. Legal & General Group Plc boosted its holdings in Maze Therapeutics by 23.0% in the 3rd quarter. Legal & General Group Plc now owns 5,219 shares of the company’s stock valued at $135,000 after purchasing an additional 977 shares during the period. Bank of America Corp DE boosted its holdings in Maze Therapeutics by 33.6% in the 2nd quarter. Bank of America Corp DE now owns 5,782 shares of the company’s stock valued at $71,000 after purchasing an additional 1,455 shares during the period. Russell Investments Group Ltd. grew its position in shares of Maze Therapeutics by 947.8% during the 3rd quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock worth $49,000 after purchasing an additional 1,725 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. bought a new position in shares of Maze Therapeutics during the third quarter worth approximately $52,000.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the stock. Wall Street Zen downgraded shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, February 7th. HC Wainwright restated a “buy” rating on shares of Maze Therapeutics in a research note on Wednesday, January 28th. Lifesci Capital raised Maze Therapeutics to a “strong-buy” rating in a report on Thursday, December 18th. BTIG Research reiterated a “buy” rating and set a $46.00 target price on shares of Maze Therapeutics in a research report on Monday, March 9th. Finally, Mizuho raised Maze Therapeutics to a “strong-buy” rating in a report on Wednesday, March 11th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $54.63.

Maze Therapeutics Stock Down 3.1%

NASDAQ:MAZE opened at $50.21 on Monday. Maze Therapeutics, Inc. has a twelve month low of $6.71 and a twelve month high of $52.86. The stock’s 50-day simple moving average is $44.82 and its 200 day simple moving average is $35.90. The firm has a market capitalization of $2.42 billion, a PE ratio of -2.40 and a beta of 4.46.

Insider Transactions at Maze Therapeutics

In other news, CMO Harold Bernstein sold 45,000 shares of the firm’s stock in a transaction that occurred on Monday, December 29th. The shares were sold at an average price of $40.56, for a total value of $1,825,200.00. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Atul Dandekar sold 72,400 shares of Maze Therapeutics stock in a transaction that occurred on Monday, December 29th. The shares were sold at an average price of $40.56, for a total transaction of $2,936,544.00. Following the sale, the insider directly owned 10,503 shares in the company, valued at $426,001.68. This trade represents a 87.33% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 230,000 shares of company stock valued at $9,768,292.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.